Multi-antibiotic ResistanceNCT04181112
Fecal Transplant for MDRO Decolonization
A study testing Fecal Microbiota Transplantation (FMT) in people with Multi-antibiotic Resistance, run by University of British Columbia at 2 sites in Canada.
Trial summary
This is a trial designed to determine whether fecal microbiota transplantation (FMT) can eliminate highly drug-resistant bacteria from the intestinal tract of renal transplant patients. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Multi-antibiotic Resistance
- What is being tested?
- Fecal Microbiota Transplantation (FMT)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 90 participants
- Where
- 2 sitesCanada
- Study dates
- 4 Nov 2019to Nov 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Renal transplant patient inclusion criteria:
- 18 years or older
- Able to provide informed consent
- Positive for one of the target MDRO by rectal or stool culture tests
FMT stool donor inclusion criteria:
- Able to provide informed consent
- Able to complete donor screening
- Able to adhere to FMT stool collection and testing procedures
Renal transplant patient exclusion criteria:
- Still in hospital at week 7 following organ transplantation
- Pregnant or planning to become pregnant
- Breastfeeding
- Participating in another interventional or investigational study
- Neutropenic (ANC < 0.5)
- Presence of colostomy or ileostomy
- Has an active intestinal infection
- Fever > 38.0 or white blood count (WBC) count > 15,000
- Are taking a non-dietary probiotic supplement
- Require or are expected to require systemic antimicrobial therapy other than Pneumocystis prophylaxis or cytomegalovirus (CMV) therapy during the study period
- Has a severe underlying disease with anticipated survival less than 6 months
- Are unable to tolerate FMT or enema for any reason, or where their physician believes for any reason that FMT might pose a health risk to the subject
- Subjects who report a history of anaphylactoid food allergy will not be excluded but these allergies will be noted and donors will be required to avoid ingestion of these foods for at least three days prior to donation
FMT stool donor exclusion criteria:
- Presence of any of the following by stool examination: vancomycin-resistant Enterococci (VRE), Salmonella, Shigella, shiga toxin-producing E. coli, Yersinia, Campylobacter, extended spectrum beta-lactamase (ESBL) producing organisms or carbapenemase-producing Enterobacteriaceae (CRE), pathogenic ova or parasites, C. difficile toxin B (by PCR), or rotavirus, adenovirus and norovirus
- History of any type of active cancer aside from melanoma
- Risk factors for acquisition of HIV, syphilis, Hepatitis B, Hepatitis C, prion or any neurological disease as determined by the donor questionnaire
- History of gastrointestinal comorbidities, e.g., inflammatory bowel disease, irritable bowel syndrome, chronic constipation or diarrhea, or colostomy or ileostomy
- Receipt of blood transfusion from a country other than Canada in the preceding 6 months
- Antibiotic use or any systemic immunosuppressive agents in the 3 months prior to stool donation
- Receipt of any live vaccine within 3 months prior to stool donation
- Any current or previous medical or psychosocial condition or behaviors which in the opinion of the investigator may pose risk to the recipients or the donor
Trial locations and contacts
2 sites in 1 country.
Canada2 sites, 1 recruiting
- Active, not recruiting
Providence Health Care - St. Paul's Hospital
Vancouver, British Columbia
- Recruiting
Vancouver Coastal Health - Vancouver General Hospital
Vancouver, British Columbia
Theodore Steiner, MD
About this study
Official title: Fecal Microbiota Transplantation (FMT) for Intestinal Decolonization of Multidrug-resistant Opportunistic Pathogens
This is a trial designed to determine whether fecal microbiota transplantation (FMT) can eliminate highly drug-resistant bacteria from the intestinal tract of renal transplant patients. The primary goal of this study is to test whether oral gut decontamination followed by FMT using enema delivery will result in decolonization of the intestinal tract of renal transplant patients shortly after solid organ transplantation, thereby preventing difficult to treat post-transplant infections.
Read the detailed description
Contact the study principal investigator for the study protocol.
- Conditions
- Multi-antibiotic Resistance
- Being tested
- Fecal Microbiota Transplantation (FMT)
- Keywords
- Fecal Microbiota Transplantation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Fecal Microbiota Transplantation (FMT)Biological
FMT using retention enema
| Study group | Role | What they receive |
|---|---|---|
| Fecal microbiota transplantation | Experimental | Not described Receives: Biological: Fecal Microbiota Transplantation (FMT) |
| Fecal microbiota transplantation with antibiotic pre-treatment | Experimental | Not described Receives: Biological: Fecal Microbiota Transplantation (FMT) |
| No intervention follow-up | No intervention | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
The elimination of the target multi-drug resistant organism (MDRO), using culture and molecular test-based screening of recipient stool, at both the 14 and 30 days post-FMT.
Measured: 3 years
Secondary outcomes (3)
Compare proportions, type and timing of adverse events post-FMT
Measured: 3 years
Proportions of recolonization over 180 days
Measured: 3 years
Timing of recolonization over 180 days
Measured: 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Nov 2019
- Study start4 Nov 2019
- Primary completionNov 2022 (estimated)
- Study completionNov 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Multi-antibiotic ResistanceStudies of the same condition, open and under way.
- More trials run by University of British ColumbiaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 90 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of British Columbia
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Amee Manges, University of British Columbia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04181112
- Sponsor's protocol ID
- H19-00782 FMT.MDRO.RCT.1
- Status last verified
- Oct 2021
- First submitted
- 26 Nov 2019
- Last updated
- 6 Oct 2021
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 6 Oct 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Fecal Microbiota Transplantation (FMT) for Intestinal Decolonization of Multidrug-resistant Opportunistic Pathogens
- ClinicalTrials.gov ID
- NCT04181112
- Acronym / sponsor ID
- H19-00782 FMT.MDRO.RCT.1
- Conditions
- Multi-antibiotic Resistance
- Keywords
- Fecal Microbiota Transplantation
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 90 participants (estimated)
- Lead sponsor
- University of British ColumbiaUniversity, hospital or other
- Study start
- 4 Nov 2019 (actual)
- Primary completion
- Nov 2022 (estimated)
- Study completion
- Nov 2023 (estimated)
- First posted
- 29 Nov 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a trial designed to determine whether fecal microbiota transplantation (FMT) can eliminate highly drug-resistant bacteria from the intestinal tract of renal transplant patients. The primary goal of this study is to test whether oral gut decontamination followed by FMT using enema delivery will result in decolonization of the intestinal tract of renal transplant patients shortly after solid organ transplantation, thereby preventing difficult to treat post-transplant infections.
Detailed description
Contact the study principal investigator for the study protocol.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Fecal microbiota transplantation | Experimental | Biological: Fecal Microbiota Transplantation (FMT) |
| Fecal microbiota transplantation with antibiotic pre-treatment | Experimental | Biological: Fecal Microbiota Transplantation (FMT) |
| No intervention follow-up | No intervention | – |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Fecal Microbiota Transplantation (FMT)FMT using retention enema | Biological | Fecal microbiota transplantation, Fecal microbiota transplantation with antibiotic pre-treatment |
Primary outcome
The elimination of the target multi-drug resistant organism (MDRO), using culture and molecular test-based screening of recipient stool, at both the 14 and 30 days post-FMT.
Time frame: 3 years
3 secondary outcomes
Compare proportions, type and timing of adverse events post-FMT
Time frame: 3 years
Proportions of recolonization over 180 days
Time frame: 3 years
Timing of recolonization over 180 days
Time frame: 3 years
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Oct 2021.
- Individual participant dataSharing planned: Undecided
Related trials for Multi-antibiotic Resistance
Recruiting
Clean Trial - Chlorination to Reduce Enteric and Antibiotic Resistant Infections in Neonates
Sepsis, Neonatal Mortality
RecruitingPhase 1
A Phase 1 Study of the Safety and Tolerability of Single and Multiple Ascending Doses of BWC0977 in Healthy Volunteers
Infectious Diseases, Antimicrobial Drug Resistance
RecruitingPhase 3
Feasibility of the Application of a New Six-month Treatment for Multidrug-resistant Tuberculosis (MDR-TB) Patients in France (FAST-MDR)
MDR-TB, Tuberculosis Multi Drug Resistant Active
Not yet recruitingObservational study
Systemic Traditional Chinese Medicine in Multidrug-Resistant Bacterial Pneumonia
Multi Drug Resistant Infections, Pneumnia
Not yet recruiting
Impact of Three Probabilistic Antibiotic Therapy on Digestive Microbiota and Colonization With Multi-resistant Bacteria
Osteoarticular Material Infection
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Fecal Microbiota Transplantation (FMT) in people with Multi-antibiotic Resistance, run by University of British Columbia at 2 sites in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 6 Oct 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Amee Manges, MPH, PhD (604 707 2743, amee.manges@ubc.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The elimination of the target multi-drug resistant organism (MDRO), using culture and molecular test-based screening of recipient stool, at both the 14 and 30 days post-FMT. (time frame: 3 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Oct 2021.